Daniel L. Flynn PhD is recently retired from Deciphera Pharmaceuticals, Inc., a company he founded in 2003. While at Deciphera during 2003-2023, he held positions of Chief Executive Officer and more recently Executive Vice President and Chief Scientific Officer. He has 40 years of experience within the pharma and biotechnology industry. His research interests are focused … Read more
Casey Cunningham, MD is the Chief Scientific Officer of Santé Ventures. Dr. Cunningham received his fellowship training in oncology and hematology at the Harvard Medical School, where he subsequently served on the faculty for a number of years. In 1999, he became the Associate Director of the Mary Crowley Cancer Research Institute in Dallas, Tx. … Read more
Laurent Humeau is Chief Scientific Officer at Inovio. He works to ensure continuous and strategic growth of INOVIO’s pipeline by introducing a constant flow of innovative concepts and cycling them from early-stage discovery and development through clinical application and patient monitoring. He provides technical and strategic leadership across multiple teams that are essential to upstream … Read more
José Ochoa is a Venture Partner at Flerie Invest, a European biotech and pharma investor managing a portfolio of more than 25 companies in the US, UK, Sweden and Israel. With over 25 years of experience in the life sciences sector, José has successfully executed a variety of transactions, including mergers, acquisitions, joint ventures, and … Read more
Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer. He held positions of increasing responsibility after joining the company in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine … Read more
